论文部分内容阅读
糖皮质激素(Glucocorticoid,GC)是机体靶器官产生生物效应的第一信使。它对机体发挥的生物作用最为广泛。很久以来,常用于临床上各个系统多种疾病的诊断和治疗。业已证实,激素对靶细胞的治疗效应必须通过特异性受体的介导而实现。在对乳腺癌的治疗学研究中已发现,靶器官靶细胞所含特异性激素受体的数量及其功能状态可以影响激素效应的发挥。糖皮质激素受体(Glucocorticoid Receptor,GCR)是细胞内能与GC特异性结合并可产生生物学效应的位点。近年来,受体的放射配体(Ligand)结合测定方
Glucocorticoid (GC) is the first messenger of the biological effects of the target organ in the body. It plays the most extensive role in the body’s biological. For a long time, commonly used in clinical diagnosis and treatment of various diseases in various systems. It has been demonstrated that the therapeutic effect of hormones on target cells must be mediated through specific receptors. In the therapeutic study of breast cancer, it has been found that the number of specific hormone receptors contained in the target organ target cells and their functional status can influence the exertion of hormone effects. Glucocorticoid receptor (Glucocorticoid Receptor, GCR) is the site of intracellular GC-specific binding and biological effects. In recent years, the receptor’s radioligand (Ligand) binds to the assay side